Erratum: Sertraline for the treatment of depression in Alzheimer disease: Genetic influences (Journal of Geriatric Psychiatry and Neurology (2011) 24:4 (222-228) DOI: 10.1177/0891988711422527);Sertraline for the treatment of depression in alzheimer disease: Genetic influences

Journal of Geriatric Psychiatry and Neurology

Volumn 24, Issue 4, 2011, Pages 222-228

  Peters, Matthew E ^a   Vaidya, Vijay ^b   Drye, Lea T ^b   Rosenberg, Paul B ^a   Martin, Barbara K ^b   Porsteinsson, Anton P ^c   Frangakis, Constantine E ^b   Mintzer, Jacobo ^d,e   Weintraub, Daniel ^f   Schneider, Lon S ^g   Rabins, Peter V ^a   Munro, Cynthia A ^a   Meinert, Curtis L ^b   Lyketsos, Constantine G ^a   Dimitri, Avramopoulos ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alzheimer disease; antidepressant; dementia; depression; randomized trial; sertraline

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DNA; HTR2A RECEPTOR; HTR2C RECEPTOR; PLACEBO; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN TRANSPORTER 5HTT; SERTRALINE; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE DURATION; DNA EXTRACTION; DRUG EFFICACY; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84855426968     PISSN: 08919887     EISSN: 15525708     Source Type: Journal    
DOI: 10.1177/0891988712464918     Document Type: Erratum

References (34)

1. Rabins PV, Lyketsos CG, Steele CD Practical Dementia Care. 2 nd ed. New York, NY: Oxford University Press; 2006. New York, NY: Oxford University Press ; 2006 :
2. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002 ; 288 (12). 1475-1483
3. Steinberg M, Shao H, Zandi P, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache county study. Int J Geriatr Psychiatry. 2008 ; 23 (2). 170-177 (Pubitemid 351308497)
4. Lee HB, Lyketsos CG. Depression in Alzheimer's disease: heterogeneity and related issues. Biol Psychiatry. 2003 ; 54 (3). 353-362 (Pubitemid 37270616)
5. Rosenberg PB, Onyike CU, Katz IR, et al. Clinical application of operationalized criteria for 'Depression of Alzheimer's Disease'. Int J Geriatr Psychiatry. 2005 ; 20 (2). 119-127 (Pubitemid 40277890)
6. Olin JT, Katz IR, Meyers BS, Schneider LS, Lebowitz BD. Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background. Am J Geriatr Psychiatry. 2002 ; 10 (2). 129-141
7. Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003 ; 60 (7). 737-746 (Pubitemid 36818637)
8. Lyketsos CG, Sheppard JM, Steele CD, et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Am J Psychiatry. 2000 ; 157 (10). 1686-1689
9. Magai C, Kennedy G, Cohen CI, Gomberg D. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. Am J Geriatr Psychiatry. 2000 ; 8 (1). 66-74 (Pubitemid 30036843)
10. Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr. 2001 ; 13 (2). 233-240 (Pubitemid 32703334)
11. Reifler BV, Teri L, Raskind M, et al. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry. 1989 ; 146 (1). 45-49 (Pubitemid 19033221)
12. Roth M, Mountjoy CQ, Amrein R. Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Br J Psychiatry. 1996 ; 168 (2). 149-157
13. Martin BK, Frangakis CE, Rosenberg PB, et al. Design of depression in Alzheimer's disease study-2. Am J Geriatr Psychiatry. 2006 ; 14 (11). 920-930 (Pubitemid 44706410)
14. Rosenberg PB, Drye LT, Martin BK, et al. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010 ; 18 (2). 136-145
15. Weintraub D, Rosenberg PB, Drye LT, et al. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010 ; 18 (4). 332-340
16. Drye LT, Martin BK, Frangakis CE, et al. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study +/- 2 (DIADS-2)?. Int J Geriatr Psychiatry. 2010 ; 26 (6). 573-583
17. Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl). 2004 ; 174 (4). 525-529 (Pubitemid 39119341)
18. Ng CH, Easteal S, Tan S, Schweitzer I, Ho BK, Aziz S. Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Prog Neuropsychopharmacol Biol Psychiatry. 2006 ; 30 (5). 953-957 (Pubitemid 43795359)
19. Hwang JP, Tsai SJ, Hong CJ, Yang CH, Lirng JF, Yang YM. The Val66Met polymorphism of the brain-derived neurotrophic-factor gene is associated with geriatric depression. Neurobiol Aging. 2006 ; 27 (12). 1834-1837
20. Tsai SJ, Cheng CY, Yu YW, Chen TJ, Hong CJ. Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet B Neuropsychiatr Genet. 2003 ; 123B (1). 19-22 (Pubitemid 37323258)
21. Wilkosz PA, Kodavali C, Weamer EA, et al. Prediction of psychosis onset in Alzheimer disease: the role of depression symptom severity and the HTR2A T102C polymorphism. Am J Med Genet B Neuropsychiatr Genet. 2007 ; 144B (8). 1054-1062 (Pubitemid 350207781)
22. Lappalainen J, Long JC, Virkkunen M, Ozaki N, Goldman D, Linnoila M. HTR2C Cys23Ser polymorphism in relation to CSF monoamine metabolite concentrations and DSM-III-R psychiatric diagnoses. Biol Psychiatry. 1999 ; 46 (6). 821-826 (Pubitemid 29460909)
23. Ramanathan S, Glatt SJ. Serotonergic system genes in psychosis of Alzheimer dementia: meta-analysis. Am J Geriatr Psychiatry. 2009 ; 17 (10). 839-846
24. Serretti A, Benedetti F, Zanardi R, Smeraldi E. The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Prog Neuropsychopharmacol Biol Psychiatry. 2005 ; 29 (6). 1074-1084 (Pubitemid 41080134)
25. Borroni B, Grassi M, Archetti S, et al. BDNF genetic variations increase the risk of Alzheimer's disease-related depression. J Alzheimers Dis. 2009 ; 18 (4). 867-875
26. Taylor WD, McQuoid DR, Ashley-Koch A, et al. BDNF Val66Met genotype and 6-month remission rates in late-life depression. Pharmacogenomics J. 2011 ; 11 (2). 146-154
27. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association ; 2000 :
28. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 ; 12 (3). 189-198
29. Research consent for cognitively impaired adults: recommendations for institutional review boards and investigators. Alzheimer Dis Assoc Disord. 2004 ; 18 (3). 171-175
30. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's disease cooperative study-clinical global impression of change. Alzheimer Dis Assoc Disord. 1997 ; 11 (suppl 2). 22
31. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. Biol Psychiatry. 1988 ; 23 (3). 271-284 (Pubitemid 18047596)
32. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994 ; 44 (12). 2308
33. Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 ; 33 (2). 262
34. Schwab M, Kaschka WP, Spina E Pharmacogenetics in Psychiatry. S. Karger AG ; 2010 :